Ryan Savitz - 24 Jan 2024 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Adam Veness, as attorney-in-fact for Ryan Savitz
Issuer symbol
DNTH
Transactions as of
24 Jan 2024
Net transactions value
$0
Form type
4
Filing time
26 Jan 2024, 16:41:24 UTC
Previous filing
13 Sep 2023
Next filing
28 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Award $0 +120,000 $0.000000 120,000 24 Jan 2024 Common Stock 120,000 $17.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.